Dranitsaris and Lacouture developed a score for predicting the risk of diarrhea in a breast cancer patient treated with lapatinib and capecitabine. The authors are from Augmentium Pharma Consulting and Memorial Sloan-Kettering Cancer Center.
Patient selection: breast cancer treated with lapatinib and capecitabine
Outcome: diarrhea Grade 2 or greater
Parameters:
(1) age in years
(2) skin metastases at baseline
(3) month of year when first cycle started
(4) Grade 1 diarrhea in previous cycle
(5) current cycle number
|
Parameter |
Finding |
Points |
|
age in years |
|
<years> |
|
skin metastases |
No |
0 |
|
|
Yes |
- 50 |
|
month cycle started |
April, May, June (second quarter) |
25 |
|
|
other |
0 |
|
Grade 1 diarrhea |
No |
0 |
|
|
Yes |
25 |
|
current cycle number |
|
<cycle> * (-5) |
total score =
= 100 + SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 250
• The higher the score the greater the risk for diarrhea.
• A score > 125 was considered “high risk” (risk > 4.2%).
|
Score |
Risk (Observed) |
|
<= 75 |
0.5% |
|
76 to 125 |
2.4% |
|
126 to 175 |
9% |
|
> 175 |
25% |
|
Score |
|
|
< 100 |
< 1.8% |
|
100 to 200 |
(0.002309 * ((score)^2)) - (0.4654 * (score)) + 25.36 |
|
> 200 |
> 24.8% |
Specialty: Hematology Oncology, Gastroenterology
